A study investigating CD133 mRNA expression in residual cancer cells after chemoradiotherapy (CRT) in rectal cancer showed how elevated post-CRT CD133 expression was associated with poor disease-free survival, and patients who developed distant recurrence had a higher post-CRT CD133 compared with those patients without recurrence. The gene discussed is PROM1; the disease is rectal cancer.